Last reviewed · How we verify
Anti-coagulation therapy — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Anti-coagulation therapy (Anti-coagulation therapy) — Boston Scientific Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-coagulation therapy TARGET | Anti-coagulation therapy | Boston Scientific Corporation | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-coagulation therapy CI watch — RSS
- Anti-coagulation therapy CI watch — Atom
- Anti-coagulation therapy CI watch — JSON
- Anti-coagulation therapy alone — RSS
Cite this brief
Drug Landscape (2026). Anti-coagulation therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-coagulation-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing